3-ethyl-2-[(3-ethyl-6-sulfo-2H-1,3-benzothiazol-2-yl)amino]-2H-1,3-benzothiazole-6-sulfonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 3-ethyl-2-[(3-ethyl-6-sulfo-2H-1,3-benzothiazol-2-yl)amino]-2H-1,3-benzothiazole-6-sulfonic acid
• 化学式: C₁₈H₂₁N₃O₆S₄
• 分子量: 503.6
• InChiKey: NPDAEDRSIHGVBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  195
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
  申请人：SUGEN, Inc.

  公开号：US20040186160A1

  公开（公告）日：2004-09-23

  The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.

  本发明涉及一类吲哚酮化合物，即六氢-环庚-吡咯酮氧吲哚，其作为蛋白激酶抑制剂具有用途。
• 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
  申请人：Sugen, Inc.

  公开号：US20030130235A1

  公开（公告）日：2003-07-10

  The present invention relates to certain 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

  本发明涉及抑制激酶，特别是VEGFR和/或PDGFR激酶的某些3-[4-(取代杂环基)-吡咯-2-基甲基亚苄酮]衍生物。还公开了包含这些化合物的药物组合物、利用包含这些化合物的药物组合物治疗激酶介导的疾病的方法，以及它们的制备方法。
• Combination therapy for the treatment of cancer
  申请人：Pharmacia Corporation

  公开号：US20030216410A1

  公开（公告）日：2003-11-20

  The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.

  本发明涉及使用蛋白酪氨酸激酶抑制剂与环氧合酶抑制剂，特别是环氧合酶-2选择性抑制剂，联合治疗或预防肿瘤性疾病的方法。
• Pyrrole substituted 2-indolinone protein kinase inhibitors
  申请人：——

  公开号：US20020156292A1

  公开（公告）日：2002-10-24

  The present invention relates to pyrrole substituted 2 -indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。
• Pharmaceutical formulations comprising indolinone derivatives
  申请人：SUGEN INCORPORATED

  公开号：US20030176399A1

  公开（公告）日：2003-09-18

  The present invention is directed to formulations comprising 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Methods of treating diseases related to abnormal PK activity utilizing the formulations comprising these compounds and methods of making these formulations are also disclosed.

  本发明涉及含有3-(吡咯-2-基甲亚基)-2-吲哚酮衍生物的配方，该配方调节蛋白激酶（“PKs”）的活性。还公开了利用含有这些化合物的配方治疗与异常PK活性相关的疾病的方法，以及制备这些配方的方法。